Aminoleban Injection 1s

What it is used for: Liver Disorder.

Indications as listed by the manufacturer: Treatment of hepatic encephalopathy in patients with chronic liver disease.

How it works: AMINOLEBAN normalized the pattern of free amino acids in the plasma and brain, improved serotonin metabolism in the brain and corrected a sleep-wakefulness pattern in a rat model of chronic hepatic insufficiency which underwent a portacaval shunt operation. 2. When infused to portacaval-shunted rats loaded with ammonia, AMINOLEBAN improved EEG pattern and corrected amine metabolism in the brain as evidenced by correction of the free amino acid pattern in the plasma and brain and by suppression of an increase of the false neurotransmitter octopamine.

Active ingredient: Aminoacetic acid 9g, L-alanine 7.5g, L-arginine HCl 7.3g, L-arginine 6g, L-cysteine HCl monohydrate 0.4g, L-cysteine 0.3g, L-histidine HCl monohydrate 3.2g, L-histidine 2.4g, L-isoleucine 9g, L-leucine 11g, L-Lysine HCl 7.6g, L-lysine 6.1 g, L-methionine 1g, L-phenylalanine 1g, L-proline 8g, L-serine 5g, L-threonine 4.5g, L-tryptophan 0.7g, L-valine 8.4g.

Reported side effects: 1) Clinically significant adverse reactions: (1) Hypoglycemia: Hypoglycemia may occur. If the patient develops hypoglycemia, glucose should be administered promptly by intravenous infusion. In addition, appropriate nutrition management is required in such patients. (2) Hyperammonemia: Hyperammonemia has been reported. If the patient develops persistent hyperammonemia during the administration of AMINOLEBAN®,discontinue administration and take measures to eliminate other nitrogen sources.2) Other adverse reactions : (1) Hypersensitivity : Symptoms such as skin rash may occur rarely. In the event of skin rash, discontinue the administration and institute appropriate treatment. (2) Gastrointestinal : Symptoms such as nausea and vomiting may occur infrequently. (3) Cardiovascular : Symptoms such as chest discomfort and palpitation may occur infrequently. (4) Metabolic : The nitrogen content of this preparation may induce a transient increase in blood ammonia concentrations. (5) Large dose and rapid administration : Acidosis may occur when large doses are administered rapidly.(6) Others : Chills, fever, headache and vascular pain may infrequently occu

Known drug interactions: Some medicines and this medicine may interfere with each other. Your doctor or pharmacist may have more information on medicines to be careful with or to avoid while using this medicine .

The usual adult dose of AMINOLEBAN is 500-1000 mL per dose by intravenous drip infusion. The usual peripheral infusion rate is 500 mL over 180-300 minutes in adults (approx. 25-40 drops per minute). For total parenteral nutrition, 500-1000 mL of the injection should be suitable combined with dextrose or other solutions and administered over 24 hours via the central vein. The dosage may be adjusted depending on the patient's age, symptoms and body weight.

Active ingredient: Aminoacetic acid 9g, L-alanine 7.5g, L-arginine HCl 7.3g, L-arginine 6g, L-cysteine HCl monohydrate 0.4g, L-cysteine 0.3g, L-histidine HCl monohydrate 3.2g, L-histidine 2.4g, L-isoleucine 9g, L-leucine 11g, L-Lysine HCl 7.6g, L-lysine 6.1 g, L-methionine 1g, L-phenylalanine 1g, L-proline 8g, L-serine 5g, L-threonine 4.5g, L-tryptophan 0.7g, L-valine 8.4g.

Store this medicine at room temperature, away from direct light and heat.

Manufactured by Aminoleban Pharma (Pvt) Ltd.. Country of origin: Switzerland.